Allergan AGN

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. Headlines
    1. One less potential competitor for Botox


      Mon, 14 Apr 2014

      Johnson and Johnson ( JNJ ) discontinues its development of PurTox , a neurotoxin intended to compete with Allergan 's ( AGN ) $2B anti-wrinkle blockbuster. The company acquired the rights to the drug in 2009 with its buy of Mentor Corp

    2. J&J says halting development of Botox rival


      Fri, 11 Apr 2014

      April 11 (Reuters) - Johnson & Johnson said on Friday it was ending its efforts to bring to market a rival drug to Allergan Inc 's popular Botox anti-wrinkle treatment.

    3. After Bristol Myers' Bydureon Success, The Next Step Is Sustained Release Insulin


      Wed, 2 Apr 2014

      include, Eli Lilly ( LLY ), Merck ( MRK ), P&G, Novartis ( NVS ), AstraZeneca ( AZN ), Sanofi-Aventis ( SNY ), Allergan ( AGN ) and Bausch & Lomb. Here's a quick rundown. Sustained Release Success Across Many Disease Indications Novartis

    4. Tonix hires seasoned drug developer


      Tue, 1 Apr 2014

      products through the development and clinical trial phases. His background includes stints at MAP Pharmaceuticals (acquired by Allergan ), Inspire Pharmaceuticals (acquired by Merck), Sepracor (acquired by Dainippon Sumitomo Pharma) as well as several members

    5. U.S. top court declines to hear patent case on glaucoma drug


      Mon, 31 Mar 2014

      WASHINGTON, March 31 (Reuters) - The U.S. Supreme Court on Monday left intact an appeals court ruling that endorsed patent protections for Combigan, Allergan Inc 's glaucoma drug.

    6. Big pharma investing in regenerative medicine


      Wed, 26 Mar 2014

      areas of interest are cardiovascular disease, oncology, neurodegenerative disease, monogenic disorders and ocular disease. ( AGN ) ( AMGN ) ( BAX ) ( BIIB ) ( CELG ) ( LLY ) ( GSK ) ( JNJ ) ( NVS ) ( NVO ) ( PFE ) ( OTCQX:RHHBY ) ( SNY ) ( MRK ) ( SHPG

    7. Credit Market Outlook: Bonds Priced for the Benign


      Wed, 26 Mar 2014

      bondholders of merger targets. Specifically, we highlight Abbott Laboratories ABT (rating: AA-, narrow moat), Allergan AGN (rating: AA-, wide moat), Teva Pharmaceutical TEVA (rating: A-, narrow moat), and Zoetis ZTS (rating

    8. From Barron’s, March 24, 2014 (Part 2)


      Sat, 22 Mar 2014

      Q&A with Sam Isaly , the manager of Eaton Vance health sciences ETHSX . He still likes biotechs and pharma. His picks are AGN , ESRX, ISRG, REGN, RHHBY ; also mentioned are BIIB, GILD, PCYC, MDVN, ALPMY, ABBV, JAZZ, PRGO, ACT, JNJ, BMY

    9. SUPN: 2013 Revenues Exceed Analyst Company's Expectations; Maintaining Positive Outlook


      Sun, 16 Mar 2014

      By Cockrell Group : We are remaining positive on the outlook of Supernus Pharmaceuticals' (NASDAQ: SUPN ) shares after the Company released its 4Q13 and FY2013 results. Reported revenues for 2013 were approximately $12 million, which exceeded analyst estimates of $8.3 million. Shares of the company

    10. Analysis Of The Near-Term Value Drivers Of Spectrum Pharmaceuticals


      Fri, 7 Mar 2014

      partnerships for both development and marketing: Pfizer/Takeda for Fusilev, Bayer for Zevalin, Topotarget for Belinostat and Allergan for Apaziquone. Moreover, OncoRx is a subsidiary of SPPI located in India that functions as a dependable resource for SPPI

    « Prev12345Next »
    Content Partners